ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2660

Developing Predictive Models for the Diagnosis of VEXAS Syndrome

Daniel Montes1, Andrew C. Hanson2, Hannah Langenfeld1, Cynthia Crowson1, Mrinal Patnaik1, Ronald Go1, Alexander Hines1, Kambiz Kalantari1, Yael Kusne3, Terra Lasho2, Abhishek Mangaonkar1, Horatiu Olteanu1, Kaaren Reichard1, Megan Sullivan4, David Viswanatha1, Kenneth Warrington1 and Matthew Koster1, 1Mayo Clinic, Rochester, MN, 2Mayo Clinic, Rochester, 3Mayo Clinic, Phoenix, AZ, 4Mayo Clinic Arizona, Scottsdale, AZ

Meeting: ACR Convergence 2024

Keywords: Autoinflammatory diseases, Miscellaneous Rheumatic and Inflammatory Diseases

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 19, 2024

Title: Abstracts: Miscellaneous Rheumatic & Inflammatory Diseases II

Session Type: Abstract Session

Session Time: 11:00AM-12:30PM

Background/Purpose: VEXAS (Vacuoles, E1 enzyme, X-linked, Autoinflammatory, Somatic) syndrome is a recently identified autoinflammatory disorder with a heterogenous presentation. Patients may experience delays in diagnosis in favor of better known autoimmune or hematologic conditions. Studies focused on identifying which patients should be considered for confirmatory UBA1 testing are limited. Thus, we aimed to design predictive models to efficiently inform clinicians about when and who to test for VEXAS syndrome.

Methods: Patients with inflammatory/hematologic abnormalities who had UBA1 testing for suspected VEXAS syndrome at our institution were identified. An extensive list of clinical and laboratory features related to VEXAS syndrome was developed and abstracted from the medical records. Features were examined at two time points: within 6 months of onset of symptoms suspected to be due to VEXAS and at the time of VEXAS testing. Two multivariable models were derived via the least absolute shrinkage and selection operator (LASSO) method, with nested cross-validation used to estimate performance on unseen data. A “full” LASSO model utilized all features selected by the LASSO method, and a second, 5-variable LASSO model utilized only the top 5 most discriminating features from the full model. A third, single variable model, utilizing absolute monocyte count, was also examined. Area under the receiver operating characteristic curve (AUC) analysis was used to assess each model’s ability to discriminate between positive and negative cases (presence or absence of UBA1 mutation on genetic testing respectively). Additional descriptive assessment of each model, including sensitivity, specificity, and positive and negative predictive values were estimated by maximizing Youden’s index.

Results: A total of 144 patients underwent UBA1 genetic testing for VEXAS, of which 77 patients (all men, 97.4% white, mean age 67.2 years at symptom onset) tested positive and 67 patients (82.1 % male, 94.0 % white, mean age 60.8 years at symptom onset) tested negative. Further patient characteristics are summarized in table 1. Full LASSO models selected 16 disease features and performed well (AUC 0.91, 0.92 at symptom onset and time of testing respectively). The 5- and single-variable models performed less well in nested cross-validation (AUC 0.84, 0.78 respectively) (Figure 1). The disease features utilized by each model are listed under table 2.

Conclusion: Predictive models for a diagnosis of VEXAS syndrome perform well among patients with systemic inflammatory disease undergoing UBA1 testing. While the full (16-feature) LASSO model performed optimally, the 5-feature model still had satisfactory discrimination and may be considered as a potential clinically applicable tool to guide VEXAS screening. The single variable (monocyte count) model performed less well than the multi-feature models but its discriminatory capacity highlights the importance of low monocytes among patients with systemic inflammation and its association with positive UBA1 testing. Validation of these models in additional VEXAS cohorts is needed to confirm findings.  

Supporting image 1

Table 1: Demographics and Lab Data Summary Comparing VEXAS negative and VEXAS Positive Cases; CRP, c-reactive protein; ESR, erythrocyte sedimentation rate; IQR, interquartile range; MCV, mean corpuscular volume; WBC, while blood cell; *p-values < 0.05 are considered significant; **several patients with more than one diagnosis

Supporting image 2

Figure 1A: Receiver operating characteristic (ROC) curves for the full and 5-variable lasso models and single variable (absolute monocyte count) model at symptom onset; 1B: ROC curves at time of diagnosis.

Supporting image 3

Table 2: Assessment of Model Predictive Ability; AUC, area under receiver operating characteristic curve; NPV, negative predictive value; PPV, positive predictive value; Sens, sensitivity; Spec, specificity. ± Features include white blood cell count, absolute lymphocyte count, absolute monocyte count, RF positivity, anti-CCP positivity, auricular chondritis, inflammatory skin rash, periorbital edema, weight loss, hearing loss, dysphonia, inflammatory arthritis, chondritis, inflammatory eye, and age; * Features include erythrocyte sedimentation rate, mean corpuscular volume, platelet count, absolute lymphocyte count, absolute monocyte count, auricular chondritis, inflammatory skin rash, panniculitis, periorbital edema, neutrophilic alveolitis, myocarditis, weight loss, hearing loss, dysphonia, pulmonary disease, and age; ** Features include mean corpuscular volume, auricular chondritis, inflammatory skin rash, dysphonia, and pulmonary disease.


Disclosures: D. Montes: None; A. Hanson: None; H. Langenfeld: None; C. Crowson: None; M. Patnaik: StemLine, 5; R. Go: None; A. Hines: None; K. Kalantari: None; Y. Kusne: None; T. Lasho: None; A. Mangaonkar: Bristol-Myers Squibb(BMS), 5, Incyte, 5, Novartis, 5; H. Olteanu: None; K. Reichard: None; M. Sullivan: None; D. Viswanatha: None; K. Warrington: Amgen, 2, Bristol-Myers Squibb(BMS), 5, Eli Lilly, 5, sanofi, 2; M. Koster: Amgen, 1.

To cite this abstract in AMA style:

Montes D, Hanson A, Langenfeld H, Crowson C, Patnaik M, Go R, Hines A, Kalantari K, Kusne Y, Lasho T, Mangaonkar A, Olteanu H, Reichard K, Sullivan M, Viswanatha D, Warrington K, Koster M. Developing Predictive Models for the Diagnosis of VEXAS Syndrome [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/developing-predictive-models-for-the-diagnosis-of-vexas-syndrome/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/developing-predictive-models-for-the-diagnosis-of-vexas-syndrome/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology